Canada Field Trip facilitates beneficial psychedelic-assisted therapy for cancer patient Patient participated in ketamine and psilocybin sessions through the Special Access Program from Health Canada Rowan DunneSeptember 2, 2022
Canada Filament administers psilocybin to 14 participants in Health Canada sanctioned clinical trial Clinical trial will be conducted as part of the ATMA Journey Centre's psychedelic-assisted therapist training program Rowan DunneSeptember 1, 2022
International Mind Medicine Australia receives AUD$1M grant for psychedelic research New fund will support studies on psychedelic-assisted therapies for the treatment of mental health conditions Rowan DunneAugust 23, 2022
Canada Optimi receives amendment from Health Canada permitting MDMA production Vancouver producer to supply synthetic psychedelic compounds to designated investigators and companies Rowan DunneAugust 16, 2022
International Short Wave and Sheba partner for clinical trial aimed at combatting anorexia Innovative new studies in the Middle East receive approval from Israeli Ministry of Health Rowan DunneAugust 15, 2022
Research Lobe Sciences partners with iNGENū for new clinical trials in Australia Canadian biopharmaceutical company will receive government tax incentive for studies down under Rowan DunneAugust 12, 2022
Psychedelics Serenus Global becomes Health Canada licensed psilocybin distributor Multi-disciplinary controlled substance company set to commence operations at Calgary facility Rowan DunneAugust 11, 2022
Culture Sisters in Psychedelics host inaugural summit in Vancouver this September Upcoming event said to feature powerful female speakers from broad cross-section of practices and expertise Rowan DunneAugust 10, 2022
Canada Optimi Health partners with patient advocate to launch new psilocybin product The company and Hartle will host a virtual press conference scheduled for Wednesday at 1 pm Natalia Buendia CalvilloAugust 9, 2022
Psychedelics DOSED 2 set to premiere at Vogue Theatre in Vancouver Award-winning documentary sequel to be followed by Q&A with renowned psychedelic community figures Rowan DunneJuly 29, 2022